biomarkers, and adverse clinical factors, such as incomplete lung response; these patients are stratified to more intensive therapy with additional chemotherapy agents and RT. Chemotherapy Data show that neoadjuvant and/or adjuvant chemotherapy in
Search Results
Frank Balis, Daniel M. Green, Clarke Anderson, Shelly Cook, Jasreman Dhillon, Kenneth Gow, Susan Hiniker, Rama Jasty-Rao, Chi Lin, Harold Lovvorn III, Iain MacEwan, Julian Martinez-Agosto, Elizabeth Mullen, Erin S. Murphy, Mark Ranalli, Daniel Rhee, Denise Rokitka, Elisabeth (Lisa) Tracy, Tamara Vern-Gross, Michael F. Walsh, Amy Walz, Jonathan Wickiser, Matthew Zapala, Ryan A. Berardi, and Miranda Hughes
Rodrigo Goncalves and Ron Bose
clinically for early-stage breast cancer to predict recurrence risk and guide adjuvant chemotherapy decisions. Discuss the role of genome sequencing in breast cancer. Breast cancer is a heterogeneous disease with a wide range of outcomes that are not
Bonnie S. Glisson and Cesar A. Moran
resection of LCNEC. These data, which are reviewed by Fernandez and Battafarano 24 were from an era before the common use of adjuvant chemotherapy. The rates for 5-year overall survival and for stage I vary widely, from 13% to 57% and 18% to 88
Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger
received adjuvant chemotherapy. 27 Similar percentages were seen in a SEER Medicare population-based analysis of patients with stage III colon cancer. 28 In this analysis, the documented survival of patients aged 75 to 84 years with early-stage disease
Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk
Background Treatment of early-stage breast cancer with adjuvant chemotherapy has improved survival. Landmark meta-analyses by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) initially showed a 20% to 25% relative risk reduction in
Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak
receiving standard adjuvant chemotherapy experience at least temporary amenorrhea, and as many as 50% to 70% may experience permanent ovarian failure or early menopause. 30 , 31 No standard definition for chemotherapy-induced ovarian failure exists in the
Amy A. Kirkham, Kelcey A. Bland, Holly Wollmann, Alis Bonsignore, Don C. McKenzie, Cheri Van Patten, Karen A. Gelmon, and Kristin Campbell
adjuvant chemotherapy for breast cancer, randomized controlled trials (RCTs) have demonstrated that supervised aerobic or resistance exercise training has superior effects to both usual care and home-based exercise on health-related physical fitness and QoL
Hinda Boutrid, Maryam Lustberg, Jeffrey Vandeusen, Sagar Sardesai, Daniel Stover, Robert Wesolowski, Mathew Cherian, Julie Stephens, Marilly Palettas, Evan Morgan, Mohmoud Kassem, Michael Berger, Craig A. Vargo, Bhuvaneswari Ramaswamy, and Nicole Williams
disease from invasive ductal cancer. It has been previously shown that invasive lobular cancer may not be as sensitive to adjuvant chemotherapy. We showed that in the metastatic setting there was no difference in PFS and OS among first line treatment
Himani Aggarwal, Kristin M. Sheffield, Li Li, David Lenis, Rachael Sorg, and Rebecca Miksad
of adjuvant chemotherapy vs BEV RPTL patients (47.6% vs 22.3%; P <.001). In the matched sample, median overall survival (OS) was 29.7 months (95% CI, 26.9–35.2) for LPTL patients vs 18.3 months (95% CI, 15.8–21.3) for RPTL patients ( P <.001). Median
Margaret A. Tempero
Outcomes for pancreatic cancer are becoming less discouraging with the refinement of molecular profiling, both germline and somatic, and beneficial effects seen with adjuvant chemotherapy. The NCCN Guidelines for Pancreatic Adenocarcinoma reflect these advances, and recommend that clinicians consider germline testing for all patients with pancreatic cancer and consider a molecular analysis for those with metastatic disease. The guidelines further recommend that clinicians consider adjuvant therapy with modified FOLFIRINOX (leucovorin/5-FU/irinotecan/oxaliplatin) for patients who are able to tolerate it.
